A股異動 | 創維數字漲超8.5% 2021年歸母淨利同比增9.93% 股份回購
格隆匯3月22日丨創維數字(000810.SZ)漲8.63%,14.85元,總市值158億元。創維數字21日公佈2021年年度報吿,實現營業收入人民幣108.47億元,同比增長27.49%;實現歸母淨利潤4.22億元,同比增長9.93%。公司於同日公吿,公司計劃以自有資金通過二級市場以集中競價方式回購部分社會公眾股份用於股權激勵或員工持股計劃。此次回購的資金總額不低於1億元且不超過2億元,回購價格不超過16元/股。另外,公司擬在廣東省惠州市投資建設惠州創維數字產業園一期項目,以自有資金和自籌資金投資項目不超過13.38億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.